The newest publicly traded genome editing company, Beam Therapeutics, has gotten one of its experimental sickle cell therapies to produce high levels of healthy hemoglobin in lab mice, it plans to announce at the (virtual) annual meeting of the American Society of Gene and Cell Therapy on Wednesday, paving the way for human trials.

Beam’s is one of more than two dozen sickle cell studies being presented at ASGCT. The intense activity is a dramatic turnaround: Although sickle cell disease is the most common inherited blood disorder, with an estimated 100,000 patients (mostly of African descent) in the U.S., for decades it received less scientific attention and funding support than other genetic diseases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy